Brukinsa (zanubrutinib) / Medison, BeiGene  >>  Phase 3
Welcome,         Profile    Billing    Logout  

16 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brukinsa (zanubrutinib) / BeiGene
2020-000547-31: An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the lymph nodes

Not yet recruiting
3
700
Europe
Zanubrutinib, BGB-3111, Capsule
BeiGene, Ltd., BeiGene Ltd., BeiGene, Ltd.,
B-cell malignancies, blood cancer in the lymph nodes, Diseases [C] - Cancer [C04]
 
 
SEQUOIA, NCT03336333 / 2017-001551-31: A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

Checkmark Topline results from SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia
Jul 2021 - Jul 2021: Topline results from SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia
Checkmark Presentation of data from SEQUOIA trial in CLL or SLL at ASH 2019
Dec 2019 - Dec 2019: Presentation of data from SEQUOIA trial in CLL or SLL at ASH 2019
Active, not recruiting
3
590
Europe, US, RoW
Zanubrutinib, BGB-3111, BRUKINSA, Bendamustine, Treanda, Ribomustin, and Levact, Rituximab, Rituxan, MabThera, Venetoclax, Venclexta, Venclyxto
BeiGene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/21
09/26
ASPEN, NCT03053440 / 2016-002980-33: A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

Hourglass Dec 2023 - Dec 2023 : Data from ASPEN trial for Waldenstrom macroglobulinemia at ASH 2023
Checkmark In combination with Imbruvica for ASPEN trial
Jun 2021 - Jun 2021: In combination with Imbruvica for ASPEN trial
Checkmark Data in WM
May 2019 - May 2019: Data in WM
More
Completed
3
201
Europe, US, RoW
BGB-3111, Zanubrutinib, Brukinsa, Ibrutinib, IMBRUVICA
BeiGene
Waldenström's Macroglobulinemia
06/22
06/22
ALPINE, NCT03734016 / 2018-001366-42: A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Checkmark Data from ALPINE trial for CLL at ASH 2022
Dec 2022 - Dec 2022: Data from ALPINE trial for CLL at ASH 2022
Completed
3
652
Europe
Zanubrutinib, BGB-3111, Brukinsa, Ibrutinib, Imbruvica
BeiGene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/22
02/24
NCT05320575: Zanubrutinib for HLH

Completed
3
16
RoW
Zanubrutinib
Beijing Friendship Hospital
HLH
08/23
08/23
NCT05164770: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Recruiting
3
160
RoW
Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX
Shandong Provincial Hospital
High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma, B-cell Non Hodgkin Lymphoma, Mantle Cell Lymphoma
12/23
12/24
BRUIN-MCL-321, NCT04662255: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
NCT04980859: Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation

Not yet recruiting
3
45
NA
Zebutinib&BR or Zebutinib&FCR
Nanfang Hospital of Southern Medical University
Chronic Lymphocytic Leukemia
09/25
09/25
PEARL, NCT05179733: The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years

Recruiting
3
280
RoW
six courses of zanubrutinib, rituximab and lenalidomide, six courses of rituximab combined with low-dose CHOP
Ruijin Hospital, Wuhan Union Hospital, China, Ningbo No. 1 Hospital, National Naval Medical Center, Shanghai Fengxian District Central Hospital, YANCHENG NO.1 PEOPLE'S HOSPITAL, The First Affiliated Hospital of Nanchang University, Affiliated Hospital of Nantong University, Wuxi Branch of Ruijin Hospital, Sir Run Run Shaw Hospital, Northern Jiangsu Province People's Hospital, The First People's Hospital of Changde City, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Changzhou No.2 People's Hospital, The Affiliated Hospital of Xuzhou Medical University, Huai'an First People's Hospital, Taizhou Hospital, The First People's Hospital of Kunshan, First Affiliated Hospital of Fujian Medical University, Huadong Hospital, Henan Provincial People's Hospital, First Hospital of China Medical University, Shandong Provincial Hospital, HARBIN THE FIRST HOSPITAL, The First Hospital of Jilin University, Hunan Cancer Hospital, Qilu Hospital of Shandong University, THE FIRST AFFILIATED HOSPITAL, The Second Affiliated Hospital of Dalian Medical University, SUZHOU HONGCI HEMATOLOGY HOSPITAL
Diffuse Large B-Cell Lymphoma
12/25
12/25
BGB-3111-306, NCT04002297 / 2019-000413-36: Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

Active, not recruiting
3
510
Japan
zanubrutinib, BGB-3111, Brukinsa, bendamustine, rituximab
BeiGene
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
03/27
12/27
BGB-3111-LTE1, NCT04170283: Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

Recruiting
3
500
Europe, US, RoW
Zanubrutinib, BGB-3111, Tislelizumab, BGB-A317
BeiGene
B-cell Malignancies
11/27
12/28
MAHOGANY, NCT05100862: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Recruiting
3
750
Europe, US, RoW
Zanubrutinib, BGB-3111, Brukinsa, Rituximab, Rituxan, MabThera, Ruxience, Truxima, Lenalidomide, Revlimid, Obinutuzumab
BeiGene
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
07/28
06/30
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting
3
120
Europe
Rituximab, Truxima, Zanubrutinib, Brukinsa
International Extranodal Lymphoma Study Group (IELSG)
Splenic Marginal Zone Lymphoma
05/29
05/29
CELESTIAL-TNCLL, NCT06073821: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Recruiting
3
640
Europe, Canada, US, RoW
Sonrotoclax, BGB-11417, Zanubrutinib, BGB-3111, Venetoclax, Obinutuzumab
BeiGene
CLL
02/32
12/32
NCT05976763: Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Recruiting
3
421
US
Zanubrutinib, Rituximab, Patient Observation, Bone Marrow Biopsy, Fludeoxyglucose F-18, Positron Emission Tomography, PET, Computed Tomography, CAT Scan, CT Scan, Magnetic Resonance Imaging, MRI, Esophagogastroduodenoscopy, EGD, Colonoscopy, Biospecimen Collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Mantle Cell Lymphoma
08/38
08/38
NCT05707377: A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

Recruiting
2/3
282
Europe, US, RoW
Zanubrutinib, BGB-3111, Tacrolimus
BeiGene
Primary Membranous Nephropathy
12/28
12/28

Download Options